Advertisement

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Varsha Gandhi, PhD, on Ibrutinib

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Apr
11
Today In Oncology
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
Invitation to Colonoscopy vs Fecal Immunochemical Test Screening for Colorectal Cancer
Study Illuminates Disparities in Treatment Survival in Metastatic Pancreatic Ductal Adenocarcinoma
American Cancer Society Launches CEO Search
Frailty Following Chemotherapy May Be Linked to Poorer Survival in Older Women With Breast Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo